PDGFRB and breast cancer: To validate the contribution of PDGFRβ in acquired resistance in this setting, we pre-treated breast cancer cells with triple combination therapy for 72 h, washed out the inhibitors and further stimulated cells with PDGF-BB ligands for a further 48 h.